About CinCor
CinCor is a company based in Cincinnati (United States) founded in 2018 by Jon Isaacsohn was acquired by Astrazeneca in January 2023. CinCor has raised $193 million across 2 funding rounds from investors including Astrazeneca, General Atlantic and CinRx Pharma. The company has 15 employees as of March 31, 2022. CinCor operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
- Headquarter Cincinnati, United States
- Employees 15 as on 31 Mar, 2022
- Founders Jon Isaacsohn
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Cincor Pharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$50.37 M (USD)-126as on Dec 31, 2021
-
EBITDA
-$42.51 M (USD)-101as on Dec 31, 2021
-
Total Equity Funding
$193 M (USD)
in 2 rounds
-
Latest Funding Round
$143 M (USD), Series B
Oct 12, 2021
-
Investors
Astrazeneca
& 14 more
-
Employee Count
15
as on Mar 31, 2022
-
Acquired by
Astrazeneca
(Jan 09, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of CinCor
Unlock access to complete
Unlock access to complete
Scientific Team
7 people
Leadership Team
3 people
Operations Team
2 people
CSO Team
1 people
Unlock access to complete
Funding Insights of CinCor
CinCor has successfully raised a total of $193M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $143 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CinCor
CinCor has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, General Atlantic and CinRx Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked |
Investor details for CinCor
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CinCor
Investment portfolio details for CinCor
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CinCor
Detailed financials for CinCor
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cincor Comparisons
Peer comparison for CinCor
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CinCor
CinCor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Detailed competitors of CinCor
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cincor
Complete news archive for CinCor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CinCor
CinCor was founded in 2018 and raised its 1st funding round 1 year after it was founded.
CinCor is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Jon Isaacsohn is the current CEO of CinCor. They have also founded this company.
CinCor is a funded company, having raised a total of $193M across 2 funding rounds to date.
As of Mar 31, 2022, the latest employee count at CinCor is 15.
CinCor was founded in 2018 in Cincinnati, United States, within the biotechnology sector. Focus is placed on developing therapeutics for cardio-renal diseases. The lead candidate, CIN-170, functions as an aldosterone synthase inhibitor targeting the renin-angiotensin-aldosterone system. Applications include treatments for hypertension, kidney diseases, and associated conditions, with operations centered in the United States.
CinCor's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
CinCor has 15 investors. Key investors include Astrazeneca, General Atlantic, CinRx Pharma, RTW Investments, and Perceptive Advisors.